TLX News: Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Pr - 31st May 2024, 9:19am

[annb0t]

TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Reported median radiographic progression-free survival (rPFS) is 8.8 months. Builds on prior data from the ProstACT SELECT[2] trial, demonstrating favourable safety profile and biodistribution[3].

MELBOURNE, Australia, May 31, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today...

>>> Read more: Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer